| ||||||||||||||||
| ||||||||||||||||
— Bristol-Myers —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "Bristol-Myers." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "Bristol-Myers"Big PharmaPfizer-Wyeth, Merck-Schering Plough. 2009 has seen some big-ticket pharma deals. Inside a carve-outBristol-Myers Squibb executes a successful divestiture. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Cravath helps Bristol feed a starved IPO marketBristol-Myers plans to raise $500M-plus selling shares in Mead Johnson Nutrition Co. Cravath's Ronald Cami and Susan Webster are advising. Mood enhancersDrug companies get a warm reception in the debt market these days. Risk Arbitrage: Feb. 9, 20092009 has begun better than it might have on the M&A front. Winter's chillLaw firms struggle to cope with deal markets that have gone deathly quiet. The comparison: Silicon Valley after the dot-com bust. Lilly and Latham join forces againGibson Dunn's Anne Benedict advised United Therapeutics in its deal with Eli Lilly. ImCloneMassachusetts' State-Boston Pension Fund has stepped in with a lawsuit to block Eli Lilly's $6.5 billion deal for ImClone. Spread too farAmid turmoil, risk arbs have absorbed a lot of bad news, but some strategic deals look likely to close, and deal demand may be building. Deep in the funkAs the credit crunch has grown worse, even the best deals are having trouble getting financed. Risk Arb updateUncertainty in banking and M&A credit markets have hammered share prices of targets of hostile bids, along with the broader stock market. No way outBristol-Myers demanded a degree of deal certainty when it auctioned its ConvaTec unit. | ||||||||||||||||
|
|
|
|
|
